These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37380971)

  • 21. Differential expression of SLITRK6 gene as a potential therapeutic target for urothelial carcinoma in particular upper tract cancer.
    Mir MA; Pandith AA; Mansoor S; Baba SM; Makhdoomi R; Ain QU; Anwar I; Para SA; Bhat AH; Koul AM; Manzoor U; Khan I; Beg A; Wani MS
    Gene; 2023 Aug; 878():147583. PubMed ID: 37353040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SERPINE2 Overexpression Is Associated with Poor Prognosis of Urothelial Carcinoma.
    Chuang HW; Hsia KT; Liao JB; Yeh CC; Kuo WT; Yang YF
    Diagnostics (Basel); 2021 Oct; 11(10):. PubMed ID: 34679626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Stromal SFRP2 Expression in Urothelial Carcinoma Confers an Unfavorable Prognosis.
    Lai HY; Chiu CC; Kuo YH; Tsai HH; Wu LC; Tseng WH; Liu CL; Hsing CH; Huang SK; Li CF
    Front Oncol; 2022; 12():834249. PubMed ID: 35372028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma.
    Chan TC; Wu WJ; Li WM; Shiao MS; Shiue YL; Li CF
    Theranostics; 2020; 10(25):11775-11793. PubMed ID: 33052246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Necdin Overexpression Predicts Poor Prognosis in Patients with Urothelial Carcinomas of the Upper Urinary Tract and Urinary Bladder.
    Chang IW; Wang YH; Wu WJ; Liang PI; Li WM; Yeh BW; Wu TF; He HL; Huang SK; Li CF
    J Cancer; 2016; 7(3):304-13. PubMed ID: 26918044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolic syndrome is associated with the risk of urothelial carcinoma from a health examination database.
    Lee HY; Tang JH; Chen YH; Wu WJ; Juan YS; Li WM; Chan TC
    Int J Clin Oncol; 2021 Mar; 26(3):569-577. PubMed ID: 33231793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EMP2 induces cytostasis and apoptosis via the TGFβ/SMAD/SP1 axis and recruitment of P2RX7 in urinary bladder urothelial carcinoma.
    Li CF; Chan TC; Pan CT; Vejvisithsakul PP; Lai JC; Chen SY; Hsu YW; Shiao MS; Shiue YL
    Cell Oncol (Dordr); 2021 Oct; 44(5):1133-1150. PubMed ID: 34339014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.
    Wu WR; Lin JT; Pan CT; Chan TC; Liu CL; Wu WJ; Sheu JJ; Yeh BW; Huang SK; Jhung JY; Hsiao MS; Li CF; Shiue YL
    Theranostics; 2020; 10(2):707-724. PubMed ID: 31903146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDCA5 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
    Chang IW; Lin VC; He HL; Hsu CT; Li CC; Wu WJ; Huang CN; Wu TF; Li CF
    Am J Transl Res; 2015; 7(4):710-22. PubMed ID: 26064439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of the cytochrome P450 4B1 protein confers a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
    Lin JT; Chan TC; Li CF; Huan SKH; Tian YF; Liang PI; Pan CT; Shiue YL
    APMIS; 2019 Apr; 127(4):170-180. PubMed ID: 30803053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer.
    Kanda M; Nomoto S; Oya H; Shimizu D; Takami H; Hibino S; Hashimoto R; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    J Exp Clin Cancer Res; 2014 Aug; 33(1):66. PubMed ID: 25096402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours.
    Yates DR; Rouprêt M; Drouin SJ; Audouin M; Cancel-Tassin G; Comperat E; Bitker MO; Cussenot O
    World J Urol; 2013 Feb; 31(1):53-9. PubMed ID: 23053209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.
    Yates DR; Catto JW
    World J Urol; 2013 Feb; 31(1):21-9. PubMed ID: 22986906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor.
    Oya H; Kanda M; Sugimoto H; Shimizu D; Takami H; Hibino S; Hashimoto R; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Nomoto S; Fujiwara M; Kodera Y
    J Gastroenterol; 2015 May; 50(5):590-600. PubMed ID: 25173447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma.
    Li J; Liang Y; Fan J; Xu C; Guan B; Zhang J; Guo B; Shi Y; Wang P; Tan Y; Zhang Q; Yuan C; Wu Y; Zhou L; Ci W; Li X
    BMC Med; 2022 Jul; 20(1):222. PubMed ID: 35843958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma.
    Li CF; Shen KH; Huang LC; Huang HY; Wang YH; Wu TF
    Pathology; 2010 Jan; 42(1):43-9. PubMed ID: 20025479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological characteristics and outcomes of synchronous renal cell carcinoma and urothelial carcinoma: A population-based analysis.
    Wu K; Liu X; Wang Y; Wang X; Li X
    Front Public Health; 2022; 10():994351. PubMed ID: 36388369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiogenesis Driven by the CEBPD-hsa-miR-429-VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression.
    Chan TC; Hsing CH; Shiue YL; Huang SK; Hsieh KL; Kuo YH; Li CF
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy.
    Yeh HC; Margulis V; Singla N; Hernandez E; Panwar V; Woldu SL; Karam JA; Wood CG; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Li CC; Ke HL; Li WM; Lee HY; Rapoport LM; Lotan Y; Kapur P; Shariat SF; Hsieh JT; Wu WJ
    Urol Oncol; 2020 May; 38(5):496-505. PubMed ID: 31862213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.